Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Recurrent Anterior Pituitary Gland Neoplasm	NCIT_C7912	[The re-emergence of a pituitary gland neoplasm after a period of remission.]
Anterior Pituitary Gland Neoplasm	NCIT_C45921	[A neoplasm arising from the anterior lobe of the pituitary gland. The vast majority are adenomas.]
Milrinone Lactate	NCIT_C29263	[A bipyridine agent with positive inotropic and vasodilator properties. Milrinone lactate selectively inhibits fraction III cyclic adenosine monophosphate (cAMP) phosphodiesterase isozymes in the heart and vascular muscles, thereby increasing cAMP and, consequently, an increase in cAMP-dependent intracellular ionized calcium and myocardium contractile force, and vasodilation in arteriolar and venous vascular smooth muscle. This agent improves hemodynamics in patients with ventricular dysfunction by increasing the stroke volume index and left ventricular contractility and by producing pulmonary vasodilation. (NCI04)]
Odontogenic Cyst	NCIT_C54220	[A cyst in the jaw that arises from tissues of tooth development.]
Mineral Oil	NCIT_C29264	[A mixture of liquid paraffinic, naphthenic and polycyclic aromatic hydrocarbons obtained from petroleum in which the amount and types of aromatic hydrocarbons is dependent on the treatment process. Untreated and mildly treated mineral oils contain the highest amount of aromatic and unsaturated compounds and are primarily used as a lubricant base oil to produce further refined oil products. Exposure to these types of mineral oils can cause rapid respiration, cyanosis, tachycardia and low-grade fever. Untreated and mildly treated mineral oils are strongly associated with an increased risk of scrotal and skin cancer but can also cause gastrointestinal, rectal, bladder and certain respiratory-tract cancers. (NCI05)]
Postcricoid Region	NCIT_C54221	[The portion of the hypopharynx that is located posteriorly to the larynx.]
Hypopharynx	NCIT_C12246	[The lower part of the pharynx that connects to the esophagus.]
Mirtazapine	NCIT_C29265	[A synthetic tetracyclic derivative of the piperazino-azepines with antidepressant activity. Although its mechanism of action is unknown, mirtazapine enhances central adrenergic and serotonergic transmission, possibly by acting as an antagonist at central presynaptic alpha 2 adrenergic inhibitory autoreceptors and heteroreceptors. This agent is a potent antagonist of 5-hydroxytryptamine type 2 (5-HT2), 5-HT3, and histamine 1 (H1) receptors, and a moderate antagonist of peripheral alpha 1 adrenergic and muscarinic receptors.]
Posterior Wall of the Pharynx	NCIT_C54222	[The dorsal portion of the fibromuscular tube that extends from the skull base to the lower border of the cricoid cartilage, and acts as a conduit for both the digestive and respiratory systems.]
Wall of the Pharynx	NCIT_C129816	[The walls of the swallowing passage.]
Mivopenim	NCIT_C29266
Moexipril Hydrochloride	NCIT_C29267	[The hydrochloride salt form of moexipril, a prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moexipril hydrochloride is hydrolized into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexipril hydrochloride also directly suppresses renin release.]
CHK1 Inhibitor PF-477736	NCIT_C68820	[A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.]
Chk1 Inhibitor	NCIT_C155927	[Any agent that inhibits the cell cycle checkpoint kinase 1 (Chk1).]
Stage II Cutaneous Melanoma AJCC v6 and v7	NCIT_C7917	[Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration. T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration. T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration. T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration. T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration. N0: No regional lymph node metastases. M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)]
Cutaneous Melanoma by AJCC v6 Stage	NCIT_C90514	[A term that refers to the staging of cutaneous melanoma, following the rules of the TNM AJCC v6 classification system.]
Mometasone Furoate	NCIT_C29268	[The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.]
Regulation	NCIT_C68821	[A rule or order issued by an authority stating what may or may not be done or how something must be done.]
Stage III Cutaneous Melanoma AJCC v6	NCIT_C7918	[Stage III includes: (Any T, N1, M0); (Any T, N2, M0); (Any T, N3, M0). N1: Metastasis in one lymph node. N2: Metastasis in two to three regional lymph nodes or intralymphatic regional metastasis without nodal metastases. N3: Metastasis in four or more regional nodes, or matted metastatic nodes, or in-transit metastasis or satellite(s) with metastasis in regional node(s). - 2003]
Mouthwash Dosage Form	NCIT_C29269	[A solution or suspension intended for oral administration, for its deodorizing or antiseptic effects in the oral cavity. Usually, the mouthwash is swished around the mouth and expelled.]